The primary purpose of the ENACT clinical trial is to compare the time to prostate cancer progression between patients treated with the FDA approved drug Enzalutamide (Xtandi) versus patients undergoing active surveillance.

Patients should consider this trial if they have been diagnosed with localized prostate cancer that has been categorized as low or intermediate risk, and they are eligible for either receiving treatment or for active surveillance. Active surveillance involves closely monitoring a patient’s condition but not providing any treatment unless the cancer progresses.

Patients who participate in the ENACT trial are randomly (by chance) assigned to a group (Arm) to receive the drug Enzalutamide or to a group (Arm) that will undergo active surveillance.  Neither the researchers nor the patient can choose who is assigned to which group.

ENACT is a phase 2 clinical trial which will enroll 222 patients. The trial began in 2016 and the primary completion date is 2019.

Possible patient benefits include preventing or slowing prostate cancer from progressing. An important benefit is that all the patients participating in this trial will be closely monitored to detect any possible progression of their cancer.

If you are interested in this trial you can take these actions:

• Use the “clinical trials glossary” and “dictionary” on PHENtrials.com for words, phrases and treatments that you may not understand.
  

• Register your interest or comments about this trial with PHEN

• More ENACT information on clinicaltrials.gov for eligibility and clinical trial locations.  

PHEN Contact: 617-481-4020

Sponsor with Contact: Astellas Pharma Inc.
800-888-7704 x5473
email: astellas.registration@astellas.com

 
* Please Note: This information is provided for education and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor.

Go Back